Skip to main content

Peer Review reports

From: Phase I dose escalation study and pilot efficacy analysis of LXI-15029, a novel mTOR dual inhibitor, in Chinese subjects with advanced malignant solid tumors

Original Submission
24 Apr 2023 Submitted Original manuscript
22 May 2023 Author responded Author comments - Binghe Xu
9 Jul 2023 Reviewed Reviewer Report
13 Jul 2023 Reviewed Reviewer Report
16 Oct 2023 Author responded Author comments - Binghe Xu
Resubmission - Version 2
22 May 2023 Submitted Manuscript version 2
17 Oct 2023 Reviewed Reviewer Report
Resubmission - Version 3
Submitted Manuscript version 3
Publishing
27 Oct 2023 Editorially accepted
6 Dec 2023 Article published 10.1186/s12885-023-11578-8

You can find further information about peer review here.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us